Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a double-blind, European Phase IIa trial in 121 patients, SC12267 missed the primary
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury